# Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

> **NCT03339700** · PHASE2 · UNKNOWN · sponsor: **Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran** · enrollment: 15 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, Adult

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT03339700
- **Lead sponsor:** Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-15
- **Primary completion:** 2020-09
- **Final completion:** 2021-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339700, "Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03339700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*